1. Home
  2. BCDA vs KXIN Comparison

BCDA vs KXIN Comparison

Compare BCDA & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioCardia Inc.

BCDA

BioCardia Inc.

N/A

Current Price

$0.83

Market Cap

15.7M

Sector

Health Care

ML Signal

N/A

KXIN

Kaixin Auto Holdings

N/A

Current Price

$2.64

Market Cap

1.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
BCDA
KXIN
Founded
N/A
2015
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail-Auto Dealers and Gas Stations
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
1.7M
IPO Year
2009
2017

Fundamental Metrics

Financial Performance
Metric
BCDA
KXIN
Price
$0.83
$2.64
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $15.50
N/A
AVG Volume (30 Days)
111.8K
★ 1.2M
Earning Date
11-12-2026
12-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $479,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.75
$0.11
52 Week High
$1.80
$22.00

Technical Indicators

Market Signals
Indicator
BCDA
KXIN
Relative Strength Index (RSI) 36.35 72.18
Support Level N/A $1.13
Resistance Level $1.04 $2.81
Average True Range (ATR) 0.09 0.25
MACD -0.00 0.09
Stochastic Oscillator 43.98 82.67

Price Performance

Historical Comparison
BCDA
KXIN

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

Share on Social Networks: